Novartis expects seven approvals over the next year

In an R&D update on Thursday, Novartis AG (NYSE:NVS; SIX:NOVN) said it expects to receive seven approvals within the next year and 18 approvals within the next two years. The seven include U.S. approval of Signifor pasireotide for acromegaly and EU approval of imatinib ( QTI571) for pulmonary arterial hypertension (PAH) and canakinumab ( ACZ885) for systemic juvenile idiopathic arthritis (sJIA). The pharma plans to submit 10 regulatory filings in the U.S. and EU within the next year, which includes the EU submission last month for chronic obstructive pulmonary disease (COPD) candidate QVA149. Novartis also expects to report data from 13 pivotal trials within the next year. ...